Overview

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Phase I/II, open-label, multicenter, prospective study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Antibodies
Antibodies, Monoclonal
Interleukin-2
Rituximab